tadalafil has been researched along with Injury, Myocardial Reperfusion in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Koka, S; Kukreja, RC; Xi, L | 1 |
| Frankenreiter, S; Friebe, A; Groneberg, D; Krieg, T; Kuret, A; Lukowski, R; Ruth, P | 1 |
| Abbate, A; Chau, VQ; Hoke, NN; Kukreja, RC; Ockaili, RA; Salloum, FN; Toldo, S; Varma, A | 1 |
| Das, A; Durrant, DE; Hoke, NN; Kukreja, RC; Salloum, FN; Varma, A | 1 |
| Das, A; Koka, S; Kukreja, RC; Salloum, FN | 1 |
| Kukreja, RC | 1 |
6 other study(ies) available for tadalafil and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dyslipidemias; Heart; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Nitrates; Nitric Oxide; Nitrites; Phosphodiesterase 5 Inhibitors; Tadalafil; Ventricular Function, Left | 2020 |
Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase.
Topics: Animals; Benzoates; Cyclic GMP; Disease Models, Animal; Enzyme Activators; Female; Ischemic Postconditioning; Large-Conductance Calcium-Activated Potassium Channels; Male; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Signal Transduction; Sildenafil Citrate; Soluble Guanylyl Cyclase; Tadalafil; Tetrazoles; Thiourea; Time Factors; Up-Regulation | 2018 |
Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide.
Topics: Animals; Carbolines; Cyclic GMP-Dependent Protein Kinases; Cystathionine beta-Synthase; Female; Hemodynamics; Hydrogen Sulfide; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Tadalafil; Ventricular Remodeling | 2009 |
Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Mellitus, Experimental; Drug Administration Schedule; Fasting; Interleukin-1beta; Male; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Necrosis; Obesity; Phosphodiesterase Inhibitors; Receptors, Leptin; Tadalafil; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice.
Topics: Animals; Apoptosis; Carbolines; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Mice; Mitochondria, Heart; Myocardial Reperfusion Injury; Myocytes, Cardiac; Nitric Oxide; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Reactive Oxygen Species; Tadalafil | 2013 |
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Carbolines; Cardiomyopathies; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Doxorubicin; Endothelium, Vascular; Enzyme Inhibitors; Erectile Dysfunction; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Ventricular Remodeling | 2007 |